CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
The CCTG Annual Spring Meeting is only 3 weeks away! If you have not registered or requested an invitation, please do so now!
On-site registration – Located on the 2nd floor of the Chelsea Hotel
If you did not receive an invitation to Spring Meeting, and you meet the eligibility criteria, you can register on-site by going to the non-registration desk.
CCTG is pleased to announce the the line up for one of the most informed events at the #CCT2026 Spring Meeting. The Plenary Session is on Friday April 24 4:30 - 5:30.
Each of the talks highlight important CCTG trials and is a Royal College of Physicians and Surgeons of Canada accredited session. Thank you to the Plenary Co-Chairs: Drs Wendy Parulekar, Annette Hay, Wei Tu, and John Queenan
Congratulations to Dr. Connor Wells who is a new investigator enrolling patients to the CRC.10 study at Alberta Health's Arthur J.E. Child Comprehensive Cancer Centre.
Dr. Rebecca Auer is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting on Saturday April 25, 5:00 pm in the Mountbatten Room at the Chelsea Hotel in Toronto. Dr Auer's lecture is titled "Research and the Courage to Hope".
This session is RCPSC accredited.
The Q1 2026 quarterly update for pending CCTG trials with approximate activation timelines are listed below. For more information between the quarterly updates, find the most recent updates and stories of recently opened CCTG trials here: https://www.ctg.queensu.ca/public/trials-development.
Congratulations to Elizabeth Eisenhauer former CCTG Director and founding Director of the Investigational New Drug program and to former Patient Representative Chair, Judy Needham on their recent acknowledgement as Women Leaders in Cancer Research by the Canadian Cancer Research Alliance (CCRA). The CCRA featured the contributions of several women recognized through the CCRA awards program and marked their achievements on International Women’s Day.
